18 results on '"Ramondo G."'
Search Results
2. The immune microenvironment in pancreatic ductal adenocarcinoma: a potential preoperative marker of lymphnodal involvement
- Author
-
De Simoni, Ottavia, primary, Ramondo, G., additional, Scarpa, M., additional, Scapinello, A., additional, Santo, L. Dal, additional, Tolin, F., additional, Lonardi, S., additional, Bergamo, F., additional, Soldà, C., additional, Fantin, A., additional, Munari, G., additional, Pilati, P., additional, Fassan, M., additional, and Gruppo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
3. The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design
- Author
-
Rossi, G P, Seccia, T M, Miotto, D, Zucchetta, P, Cecchin, D, Calò, L, Puato, M, Motta, R, Caielli, P, Vincenzi, M, Ramondo, G, Taddei, S, Ferri, C, Letizia, C, Borghi, C, Morganti, A, and Pessina, A C
- Published
- 2012
- Full Text
- View/download PDF
4. Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience
- Author
-
Dadduzio, V., primary, Rizzato, M.D., additional, Ramondo, G., additional, Vivaldi, C., additional, Milella, M., additional, Brandi, G., additional, Cereda, S., additional, Murgioni, S., additional, Cardellino, G.G., additional, Filippi, R., additional, Santini, D., additional, Pasquini, G., additional, Intini, R., additional, Vaccaro, V., additional, Palloni, A., additional, Reni, M., additional, Musettini, G., additional, Gringeri, E., additional, Aliberti, C., additional, and Zagonel, V., additional
- Published
- 2018
- Full Text
- View/download PDF
5. The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design
- Author
-
Rossi, Gp, Seccia, Tm, Miotto, D, Zucchetta, P, Cecchin, D, Calò, L, Puato, M, Motta, R, Caielli, P, Vincenzi, M, Ramondo, G, Taddei, Stefano, Ferri, C, Letizia, C, Borghi, C, Morganti, A, Pessina, Ac, Metras, Investigators, Cesari, M, Bui, F, Dessi, P, Taddei, S, Pinto, S, Belfiore, A., Rossi G.P., Seccia T.M., Miotto D., Zucchetta P., Cecchin D., Calò L., Puato M., Motta R., Caielli P., Vincenzi M., Ramondo G., Taddei S., Ferri C., Letizia C., Borghi C., Morganti A., and Pessina A.C.
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Renal function ,Kidney ,Renal Artery Obstruction ,Renal artery stenosis ,Revascularization ,Predictive Value of Tests ,Internal medicine ,medicine.artery ,Angioplasty ,Internal Medicine ,medicine ,Humans ,Prospective Studies ,Renal artery ,Antihypertensive Agents ,glomerular filtration rate ,business.industry ,angioplasty ,Kidney metabolism ,Ultrasonography, Doppler ,Atherosclerosis ,medicine.disease ,Stenosis ,Hypertension, Renovascular ,Treatment Outcome ,medicine.anatomical_structure ,Italy ,Cardiovascular Diseases ,Research Design ,Quality of Life ,Cardiology ,Technetium Tc 99m Pentetate ,Female ,Stents ,revascularization ,Radiopharmaceuticals ,Tomography, X-Ray Computed ,business ,Angioplasty, Balloon ,Biomarkers ,renal artery stenosi - Abstract
It is unclear whether revascularization of renal artery stenosis (RAS) by means of percutaneous renal angioplasty and stenting (PTRAS) is advantageous over optimal medical therapy. Hence, we designed a randomized clinical trial based on an optimized patient selection strategy and hard experimental endpoints. Primary objective of this study is to determine whether PTRAS is superior or equivalent to optimal medical treatment for preserving glomerular filtration rate (GFR) in the ischemic kidney as assessed by 99mTcDTPA sequential renal scintiscan. Secondary objectives of this study are to establish whether the two treatments are equivalent in lowering blood pressure, preserving overall renal function and regressing target organ damage, preventing cardiovascular events and improving quality of life. The study is designed as a prospective multicentre randomized, un-blinded two-arm study. Eligible patients will have clinical and angio-CT evidence of RAS. Inclusion criteria is RAS affecting the main renal artery or its major branches either >70% or, if
- Published
- 2012
6. 764P - Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience
- Author
-
Dadduzio, V., Rizzato, M.D., Ramondo, G., Vivaldi, C., Milella, M., Brandi, G., Cereda, S., Murgioni, S., Cardellino, G.G., Filippi, R., Santini, D., Pasquini, G., Intini, R., Vaccaro, V., Palloni, A., Reni, M., Musettini, G., Gringeri, E., Aliberti, C., and Zagonel, V.
- Published
- 2018
- Full Text
- View/download PDF
7. The medical and endovascular treatment of the atherosclerotic renal artery stenosis (METRAS) Study: rationale and study design
- Author
-
Rossi, Gianpaolo, Seccia, TERESA MARIA, Miotto, Diego, Zucchetta, P, Cecchin, Diego, Calo', Lorenzo, Puato, M, Motta, Raffaella, Caielli, P, Vincenzi, M, Ramondo, G, and Pessina, A. C.
- Published
- 2011
8. Safety and Efficacy of Transcatheter Arterial Chemoembolization (Tace) in Unresectable Biliary Cancer
- Author
-
Galiano, A., primary, Daniel, F., additional, Ramondo, G., additional, Polacco, M., additional, Battaglin, F., additional, Roma, A., additional, Pizzirani, E., additional, Bergamo, F., additional, Crivellari, G., additional, Gringeri, E., additional, Lonardi, S., additional, Cillo, U., additional, Zagonel, V., additional, and Aliberti, C., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Paediatric nephrology
- Author
-
Shi, H., primary, Wen, J., additional, LI, Z., additional, Elsayed, M., additional, Kamal, K., additional, Shi, H., additional, El Shal, A., additional, Youssef, D., additional, Caubet, C., additional, Lacroix, C., additional, Benjamin, B., additional, Bandin, F., additional, Bascands, J.-L., additional, Monsarrat, B., additional, Decramer, S., additional, Schanstra, J., additional, Laetitia, D.-B., additional, Ulinski, T., additional, Aoun, B., additional, Ozdemir, K., additional, Dincel, N., additional, Sozeri, B., additional, Mir, S., additional, Berdeli, A., additional, Akyigit, F., additional, Mizerska-Wasiak, M., additional, Panczyk-Tomaszewska, M., additional, Szymanik-Grzelak, H., additional, Roszkowska-Blaim, M., additional, Jamin, A., additional, Dehoux, L., additional, Monteiro, R. C., additional, Deschenes, G., additional, Bouts, A., additional, Davin, J.-C., additional, Dorresteijn, E., additional, Schreuder, M., additional, Lilien, M., additional, Oosterveld, M., additional, Kramer, S., additional, Gruppen, M., additional, Pintos-Morell, G., additional, Ramaswami, U., additional, Parini, R., additional, Rohrbach, M., additional, Kalkum, G., additional, Beck, M., additional, Carter, M., additional, Antwi, S., additional, Callegari, J., additional, Kotanko, P., additional, Levin, N. W., additional, Rumjon, A., additional, Macdougall, I. C., additional, Turner, C., additional, Booth, C. J., additional, Goldsmith, D., additional, Sinha, M. D., additional, Camilla, R., additional, Loiacono, E., additional, Donadio, M. E., additional, Conrieri, M., additional, Bianciotto, M., additional, Bosetti, F. M., additional, Peruzzi, L., additional, Conti, G., additional, Bitto, A., additional, Amore, A., additional, Coppo, R., additional, Maldyk, J., additional, Chou, H.-H., additional, Chiou, Y.-Y., additional, Bochniewska, V., additional, Jobs, K., additional, Jung, A., additional, Fallahzadeh Abarghooei, M. H., additional, Zare, J., additional, Sedighi Goorabi, V., additional, Derakhshan, A., additional, Basiratnia, M., additional, Fallahzadeh Abarghooei, M. A., additional, Hosseini Al-Hashemi, G., additional, Fallahzadeh Abarghooei, F., additional, Kluska-Jozwiak, A., additional, Soltysiak, J., additional, Lipkowska, K., additional, Silska, M., additional, Fichna, P., additional, Skowronska, B., additional, Stankiewicz, W., additional, Ostalska-Nowicka, D., additional, Zachwieja, J., additional, Girisgen, L., additional, Sonmez, F., additional, Yenisey, C., additional, Kis, E., additional, Cseprekal, O., additional, Kerti, A., additional, Szabo, A., additional, Salvi, P., additional, Benetos, A., additional, Tulassay, T., additional, Reusz, G., additional, Makulska, I., additional, Szczepanska, M., additional, Drozdz, D., additional, Zwolnska, D., additional, Tolstova, E., additional, Anis, L., additional, Alber, B., additional, Edouard, B., additional, Gerard, C., additional, Seni, K., additional, Dunia Julienne Hadiza, T., additional, Christian, S., additional, Benoit, T., additional, Francois, B., additional, Adama, L., additional, Rosenberg, A., additional, Munro, J., additional, Murray, K., additional, Wainstein, B., additional, Ziegler, J., additional, Singh-Grewal, D., additional, Boros, C., additional, Adib, N., additional, Elliot, E., additional, Fahy, R., additional, Mackie, F., additional, Kainer, G., additional, Polak-Jonkisz, D., additional, Zwolinska, D., additional, Laszki-Szczachor, K., additional, Janocha, A., additional, Rusiecki, L., additional, Sobieszczanska, M., additional, Garzotto, F., additional, Ricci, Z., additional, Clementi, A., additional, Cena, R., additional, Kim, J. C., additional, Zanella, M., additional, Ronco, C., additional, Purzyc, L., additional, Peco-Antic, A., additional, Kotur-Stevuljevic, J., additional, Paripovic, D., additional, Scekic, G., additional, Milosevski-Lomic, G., additional, Bogicevic, D., additional, Spasojevic-Dimitrijeva, B., additional, Hassan, R., additional, El-Husseini, A., additional, Sobh, M., additional, Ghoneim, M., additional, Harambat, J., additional, Bonthuis, M., additional, Van Stralen, K. J., additional, Ariceta, G., additional, Battelino, N., additional, Jahnukainen, T., additional, Sandes, A. R., additional, Combe, C., additional, Jager, K. J., additional, Verrina, E., additional, Schaefer, F., additional, Espindola, R., additional, Bacchetta, J., additional, Cochat, P., additional, Stefanis, C., additional, Leroy, S., additional, Fernandez-Lopez, A., additional, Nikfar, R., additional, Romanello, C., additional, Bouissou, F., additional, Gervaix, A., additional, Gurgoze, M., additional, Bressan, S., additional, Smolkin, V., additional, Tuerlinkx, D., additional, Stefanidis, C., additional, Vaos, G., additional, Leblond, P., additional, Gungor, F., additional, Gendrel, D., additional, Chalumeau, M., additional, Rawlins, D., additional, Simpson, J. M., additional, Arnaud, G., additional, Anne, M., additional, Stephanie, T., additional, Flavio, B., additional, Veronique, F. B., additional, Stephane, D., additional, Mumford, L., additional, Marks, S., additional, Ahmad, N., additional, Maxwell, H., additional, Tizard, J., additional, Vidal, E., additional, Amigoni, A., additional, Varagnolo, M., additional, Benetti, E., additional, Ghirardo, G., additional, Brugnolaro, V., additional, Murer, L., additional, Christine, G., additional, Degi, A., additional, Szabo, A. J., additional, Reusz, G. S., additional, Vidoni, A., additional, Ramondo, G., additional, and Miotto, D., additional
- Published
- 2012
- Full Text
- View/download PDF
10. 727P - Safety and Efficacy of Transcatheter Arterial Chemoembolization (Tace) in Unresectable Biliary Cancer
- Author
-
Galiano, A., Daniel, F., Ramondo, G., Polacco, M., Battaglin, F., Roma, A., Pizzirani, E., Bergamo, F., Crivellari, G., Gringeri, E., Lonardi, S., Cillo, U., Zagonel, V., and Aliberti, C.
- Published
- 2014
- Full Text
- View/download PDF
11. CD32 captures committed haemogenic endothelial cells during human embryonic development.
- Author
-
Scarfò R, Randolph LN, Abou Alezz M, El Khoury M, Gersch A, Li ZY, Luff SA, Tavosanis A, Ferrari Ramondo G, Valsoni S, Cascione S, Didelon E, Passerini L, Amodio G, Brandas C, Villa A, Gregori S, Merelli I, Freund JN, Sturgeon CM, Tavian M, and Ditadi A
- Subjects
- Humans, Cell Differentiation, Cell Lineage, Cells, Cultured, Embryo, Mammalian metabolism, Embryo, Mammalian cytology, Endothelial Cells metabolism, Endothelial Cells cytology, Gene Expression Profiling, Gene Expression Regulation, Developmental, Hemangioblasts metabolism, Hemangioblasts cytology, Human Embryonic Stem Cells metabolism, Human Embryonic Stem Cells cytology, Pluripotent Stem Cells metabolism, Pluripotent Stem Cells cytology, Transcriptome, Embryonic Development genetics, Hematopoiesis genetics, Receptors, IgG metabolism, Receptors, IgG genetics
- Abstract
During embryonic development, blood cells emerge from specialized endothelial cells, named haemogenic endothelial cells (HECs). As HECs are rare and only transiently found in early developing embryos, it remains difficult to distinguish them from endothelial cells. Here we performed transcriptomic analysis of 28- to 32-day human embryos and observed that the expression of Fc receptor CD32 (FCGR2B) is highly enriched in the endothelial cell population that contains HECs. Functional analyses using human embryonic and human pluripotent stem cell-derived endothelial cells revealed that robust multilineage haematopoietic potential is harboured within CD32
+ endothelial cells and showed that 90% of CD32+ endothelial cells are bona fide HECs. Remarkably, these analyses indicated that HECs progress through different states, culminating in FCGR2B expression, at which point cells are irreversibly committed to a haematopoietic fate. These findings provide a precise method for isolating HECs from human embryos and human pluripotent stem cell cultures, thus allowing the efficient generation of haematopoietic cells in vitro., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
12. Liver Metastases of Unknown Primary Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors: A Case Report and Literature Review.
- Author
-
Bimbatti D, Cavasin N, Galuppini F, Rago A, Ramondo G, Lai E, Dionese M, Erbetta E, Basso U, and Maruzzo M
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Tyrosine Kinase Inhibitors, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology, Neoplasms, Unknown Primary, Liver Neoplasms drug therapy
- Abstract
Background/aim: Renal cell carcinoma (RCC) constitutes approximately 3% of all cancers. More than 60% of RCCs are detected incidentally; one-third of patients present with regional or distant metastases, and another 20-40% of patients develop metastases after radical nephrectomy. RCC can metastasize to any organ. In contrast, metastatic RCC (mRCC) without evidence of a primary tumor is extremely rare, with only a few reported cases., Case Report: We present a case of mRCC that initially presented with multiple liver and lymph node metastases but no primary renal lesion. An impressive response to treatment was achieved with a combination of immune checkpoint inhibitors and tyrosine kinase inhibitors. A clinical, radiological, and pathological diagnostic strategy, particularly in the context of a multidisciplinary team, are crucial for reaching a definitive diagnosis. This approach allows to select the appropriate treatment, making a huge difference for a mRCC due to its resistance to standard chemotherapy., Conclusion: There are currently no guidelines available for mRCC without primary tumor. Nevertheless, a combination of TKI and immunotherapy could be the optimal first-line treatment if systemic therapy is required., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling.
- Author
-
Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, Zagonel V, Fassan M, Rosato A, and Lonardi S
- Abstract
The current level of evidence for immunotherapy in previously untreated microsatellite unstable metastatic colorectal cancer is based on recent pieces of evidence of few studies that demonstrated durable response and clinical benefit, in terms of objective response rate, disease control rate, and progression-free survival in this subgroup of patients. On the basis of combinatorial immunotherapy with nivolumab plus ipilimumab, we report the exceptional case of a complete pathological response in a 21-year-old woman presenting a clinically aggressive stage IV colorectal cancer with massive nodal and liver involvement. Extensive molecular analyses based on whole genome next-generation DNA sequencing, RNA sequencing, fluorescent multiplex immunohistochemistry, and flow cytometry provided a detailed description of tumoral and immunological characteristics of this noteworthy clinical case., Competing Interests: VZ declares a conflict of interest: consulting or Advisory Role: Bristol-Myers Squibb, MSD, Eisai, ITALFARMACO; Speakers Bureau: Roche, Bristol-Myers Squibb, Astellas Pharma, SERVIER, AstraZeneca, MSD, JANSEN, IPSEN; Research Funding: Bayer, Roche, Lilly, Astra Zeneca, BMS, Ipsen, Astellas Pharma. SL reports personal fees as speaker bureau or advisor from Amgen, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, MSD, Roche, Bristol-Myers Squibb, Pierre-Fabre, GSK and received research grants from Amgen, Merck Serono, Bayer, Roche, Lilly, Astra Zeneca, Bristol-Myers Squibb, unrelated to the current work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Bergamo, Dalla Santa, Loupakis, Cerma, Tosi, De Grandis, Dalla Pietà, Gringeri, Angerilli, Ramondo, Rago, Cecchi, Benz, Cillo, Dei Tos, Zagonel, Fassan, Rosato and Lonardi.)
- Published
- 2022
- Full Text
- View/download PDF
14. Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
- Author
-
Sommariva A, Evangelista L, Pintacuda G, Cervino AR, Ramondo G, and Rossi CR
- Subjects
- Contrast Media, Female, Humans, Male, Middle Aged, Peritoneal Neoplasms diagnostic imaging, Peritoneum diagnostic imaging, Peritoneum surgery, Radiopharmaceuticals, Reproducibility of Results, Retrospective Studies, Cytoreduction Surgical Procedures, Fluorodeoxyglucose F18, Hyperthermia, Induced, Peritoneal Neoplasms therapy, Positron Emission Tomography Computed Tomography methods, Radiographic Image Enhancement methods
- Abstract
Purpose: Aim of the study is to assess the reliability and correlation with surgical peritoneal cancer index (PCI) of combined PET/CT and ceCT scans (PET/ceCT) performed in a session in patients with peritoneal carcinomatosis candidates for cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC)., Methods: We retrospectively analyzed data collected from 27 patients with different types of peritoneal carcinomatosis candidates to CS + HIPEC who underwent FDG PET/ceCT in a single session. Two nuclear medicine physicians and two radiologists independently and blindly evaluated PET/CT and ceCT imaging, respectively. In the case of discordance, the consensus was reached by a discussion between the specialists. Moreover, the combined images were evaluated by all the specialists in consensus. The PCIs obtained from surgical look, PET/CT, ceCT, and PET/ceCT were compared with each other. The coefficients of correlation (r) were calculated. The study was conducted after approval of local ethics committee., Results: Surgical PCI was available in 21 patients. The coefficient of correlation between PCI of PET/CT and surgery was 0.528, while it resulted higher between PET/ceCT and surgery (r = 0.878), very similar to ceCT and surgery (r = 0.876). The r coefficient between surgical PCI and PET/CT was higher in patients with a non-mucinous cancer (n = 12) than the counterpart (0.601 vs. 0.303) and the addition of ceCT significantly increases the correlation (r = 0.863), which is anyway similar to ceCT alone (r = 0.856)., Conclusions: PET/ceCT as single examination is more accurate than PET/CT but not than ceCT alone for the definition of PCI in a selected group of patients candidates to CS + HIPEC.
- Published
- 2018
- Full Text
- View/download PDF
15. Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience.
- Author
-
Aliberti C, Carandina R, Sarti D, Pizzirani E, Ramondo G, Cillo U, Guadagni S, and Fiorentini G
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Hepatocellular diagnostic imaging, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Combined Modality Therapy, Doxorubicin adverse effects, Doxorubicin pharmacokinetics, Female, Humans, Liver Neoplasms diagnostic imaging, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Retreatment, Tissue Distribution, Tomography, X-Ray Computed, Treatment Outcome, Tumor Burden, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic adverse effects, Chemoembolization, Therapeutic methods, Contrast Media, Doxorubicin administration & dosage, Liver Neoplasms therapy, Microspheres
- Abstract
Aim: Primary objectives of the study were to assess the safety of transarterial chemoembolization (TACE) using DC Bead LUMI™ for the treatment of hepatocellular carcinoma and beads distribution after TACE., Patients/methods: This was a prospective observational cohort study. The study included 44 hepatocellular carcinoma patients who were treated with TACE using DC Bead LUMI. Beads distribution was monitored 1 h after TACE by CT scan., Results: TACE had no intraprocedural complications. Observed side effects were of mild intensity and included pain in 5 (11%), fever in 4 (9%) and vomiting in 2 (5%) patients. Most patients (89%) reported no adverse event. Non-target distribution was observed in only two cases (5%)., Conclusion: DC Bead LUMI allowed assessing in real time their distribution. This could prevent non-target infusion and reduce toxicity.
- Published
- 2017
- Full Text
- View/download PDF
16. Chemoembolization with Drug-eluting Microspheres Loaded with Doxorubicin for the Treatment of Cholangiocarcinoma.
- Author
-
Aliberti C, Carandina R, Sarti D, Pizzirani E, Ramondo G, Mulazzani L, Mattioli GM, and Fiorentini G
- Subjects
- Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic therapeutic use, Bile Duct Neoplasms pathology, Cholangiocarcinoma pathology, Combined Modality Therapy, Drug Delivery Systems, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Bile Duct Neoplasms therapy, Bile Ducts, Intrahepatic pathology, Chemoembolization, Therapeutic methods, Cholangiocarcinoma therapy, Doxorubicin therapeutic use, Drug Liberation, Microspheres
- Abstract
Aim: To report clinical outcomes of transarterial chemoembolization (TACE) using drug-eluting beads (DEBs) loaded with doxorubicin for the treatment of unresectable intrahepatic cholangiocarcinoma (CCA)., Patients and Methods: We treated 127 patients with doxorubicin via TACE. Inclusion criteria were: diagnosis of unresectable CCA; indication for TACE, performance status (PS) 0-2, >3 months of life expectancy, >18 years old, written consent. TACE was performed using DEBs for 109 (86%) patients and polythylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin for 18 (14%) patients., Results: Tumor response of the whole sample of 127 patients was partial response (PR) in 19 (15%) patients, stable disease (SD) in 101 (80%) and progressive disease (PD) in seven (5%) 3 months after therapy, with no complete responses. There were differences between type of embolics: PR was 7% and 77%, SD was 88% and 8%, and PD was 5% and 15%, and the disease control rate was 95% and 85% in the DEB and PEG groups, respectively. Most frequent side-effects were: abdominal pain, fever, nausea, and transaminase rise., Conclusion: TACE was effective and safe for CCA treatment, with a high disease control rate. The best response of PEG-TACE was PR, whereas it was SD for DEB-TACE., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
17. Transplant renal artery stenosis in children: risk factors and outcome after endovascular treatment.
- Author
-
Ghirardo G, De Franceschi M, Vidal E, Vidoni A, Ramondo G, Benetti E, Motta R, Ferraro A, Zanon GF, Miotto D, and Murer L
- Subjects
- Adolescent, Age Factors, Antihypertensive Agents therapeutic use, Blood Pressure, Child, Drug Therapy, Combination, Humans, Hypertension, Renovascular diagnosis, Hypertension, Renovascular epidemiology, Hypertension, Renovascular physiopathology, Italy epidemiology, Magnetic Resonance Angiography, Prevalence, Renal Artery Obstruction diagnosis, Renal Artery Obstruction epidemiology, Renal Artery Obstruction physiopathology, Retrospective Studies, Risk Factors, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Ultrasonography, Doppler, Angioplasty, Balloon, Hypertension, Renovascular therapy, Kidney Transplantation adverse effects, Renal Artery Obstruction therapy
- Abstract
Background: Transplant renal artery stenosis (TRAS) is an increasingly recognised cause of post-transplant hypertension., Methods: We retrospectively analysed 216 paediatric renal recipients transplanted between 2001 and 2011 to assess TRAS prevalence and percutaneous transluminal angioplasty (PTA) efficacy. To assess risk factors, we compared children with TRAS with a propensity score-matched cohort of recipients without TRAS., Results: Of the 216 paediatric patients who were transplanted in the study period, 44 were hypertensive (prevalence 20.3 %) and ten presented with TRAS (prevalence 4.6 %, median age at transplantation 14 years, range 6.78-17.36 years). Hypertensive patients without TRAS were prescribed one to two anti-hypertensive agents, whereas patients with TRAS required one to five medications. In the TRAS group, one recipient presented with vascular complications during surgery, and in three patients the graft had vascular abnormalities. TRAS was detected by Doppler ultrasonography (US) performed due to hypertension in nine of the patients with TRAS, but in the tenth case the TRAS was clinically silent and detected by routine Doppler-US screening. TRAS diagnosis was refined using angio-computed tomography or angio-magnetic resonance imaging. All patients underwent PTA without complications. Significant improvement after PTA was observed in the standard deviation scores for blood pressure [3.2 ± 1.4 (pre-PTA) vs. 1.04 ± 0.8 (post-PTA); p = 0.0006) and graft function [creatinine clearance: 69 ± 17.08 (pre-PTA) vs. 80.7 ± 21.5 ml/min/1.73 m(2) (post-PTA); p = 0.006] We observed no significant differences between the two cohorts for cold ischaemia time, recipient/donor weight ratio, delayed graft function, cytomegalovirus infections and acute rejection episodes., Conclusions: Our study reports a low but significant TRAS prevalence among the paediatric patients who were transplanted at our centre in the study period and confirms that PTA is an effective and safe therapeutic option in paediatric renal transplant recipients. Known risk factors do not appear to be related to the development of TRAS.
- Published
- 2014
- Full Text
- View/download PDF
18. Diffusion-weighted imaging does not predict histological grading in meningiomas.
- Author
-
Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, d'Avella D, and Manara R
- Subjects
- Adult, Aged, Aged, 80 and over, Brain pathology, Diagnosis, Differential, Female, Humans, Male, Meningeal Neoplasms surgery, Meninges pathology, Meningioma surgery, Middle Aged, Observer Variation, Predictive Value of Tests, Prognosis, Reproducibility of Results, Severity of Illness Index, Diffusion Magnetic Resonance Imaging methods, Meningeal Neoplasms pathology, Meningioma pathology, Neoplasm Invasiveness pathology
- Abstract
Purpose: This study aims to verify the reliability of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements to differentiate benign from atypical/malignant meningiomas and among different sub-types., Methods: Pre-operative DWI of 102 patients (74 females, mean age 58 years, age range 34-85 years) affected by a pathologically proven intracranial meningioma were retrospectively reviewed. DWI signal intensity of tumors was classified as hypo-, iso- or hyper-intense to grey matter. ADC values and normalised ADC(ratio) (ADC(meningioma)/ADC(normal appearing white matter)) of the neoplastic tissue (avoiding calcifications and cystic or necrotic areas) were measured by two neuroradiologists unaware of each others' reading. MRI and histological findings were compared., Results: Meningiomas were histologically graded as malignant (1%), atypical (21.5%) and benign (77.5%). Meningothelial, transitional and fibrous were the most frequent benign sub-types (44, 16 and 10 cases, respectively). There was no statistical difference between typical and atypical/malignant meningiomas when considering mean ADC values (0.964 +/- 0.192 x 10(-3) vs 0.923 +/- 0.085 x 10(-3) cm(2)/s, p = 0.3 t-Student) or ADC(ratio) (1.266 +/- 0.290 vs 1.185 +/- 0.115, p = 0.2 t-Student). ADC values or ADC(ratio) did not differ significantly among meningioma sub-types although a nearly significant difference was found between meningothelial and transitional (post hoc analysis p = 0.06). Inter-observer agreement of ADC and ADC(ratio) measurements was high (r = 0.95 and 0.92, respectively, Pearson's linear coefficient). DWI intensity did not reach a significant correlation with meningioma's grading (p = 0.08)., Conclusions: According to our study, DWI and ADC measurement do not seem reliable in grading meningiomas or identifying histological sub-types. Hence, these parameters should not be recommended for surgical or treatment planning.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.